# Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

> **NCT05556746** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 94 (actual)

## Conditions studied

- Tuberculosis, Pulmonary
- HIV

## Interventions

- **DRUG:** Bedaquiline
- **DRUG:** Clofazimine
- **DRUG:** Pyrazinamide
- **DRUG:** Delamanid
- **DRUG:** Rifampin
- **DRUG:** Isoniazid
- **DRUG:** Ethambutol
- **DRUG:** Pyrazinamide

## Key facts

- **NCT ID:** NCT05556746
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-24
- **Primary completion:** 2025-06-12
- **Final completion:** 2027-01
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2026-02-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05556746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05556746, "Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05556746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*